CERO THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2021-11-19

Name: CERO THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2021-11-19
Creator: CERO THERAPEUTICS HOLDINGS, INC.

What CERO THERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2021-11-19 (fiscal Q3 2021): 9 published measures, 15 facts as tagged in accession 0001193125-21-335132.

This filing

Form: 10-Q (quarterly report)
Filed: 2021-11-19
Fiscal period: fiscal Q3 2021
Accession: 0001193125-21-335132 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CERO THERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2021-09-30	301,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2021-09-30	277,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2021-09-30	24,000	USD
At 2021-06-30	24,000	USD
At 2021-06-07	0	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2021-09-30	0	USD
At 2021-06-07	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	0	USD	92
2021-06-08 to 2021-09-30	-1,000	USD	115
2021-06-08 to 2021-06-30	-1,000	USD	23

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2021-09-30	24,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2021-09-30	277,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	0	USD	92
2021-06-08 to 2021-09-30	1,000	USD	115

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2021-09-30	24,533	USD

Inspect the source

Entity: CERO THERAPEUTICS HOLDINGS, INC. / CIK 0001870404
Captured: 2026-09-19T11:21:59.403Z
SEC response SHA-256: 8c8c2bd97bf9d18c6c5d6af2474c4302fa2e6a98d7edbc511d62e8f44742c0ac

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001870404.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))